Search

The cardiovascular and cerebrovascular safety of ranibizumab, bevacizumab, and aflibercept for ocular diseases is unclear. This study aimed to evaluate and compare the cardiovascular and cerebrovascular safety in patients receiving ranibizumab, bevacizumab, and aflibercept for ocular disease. A cross‐sectional study was conducted from 2017 (Q1) to 2021 (Q4) in the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. The outcomes of interest were central nervous system vascular disorders, ischemic heart disease, hypertension, pulmonary hypertension, torsade de pointes/QT prolongation, embolic and thrombotic events, cardiac arrhythmias, cardiac failure, and cardiomyopathy. Data mining was performed by a disproportional method with a compression, using compressed reporting odds ratios (sRORs) with 95% confidence intervals (CIs) to measure signals. The results showed 1462 cardiovascular and cerebrovascular events associated with aflibercept, 834 with ranibizumab, and 150 with bevacizumab. Ranibizumab, bevacizumab, and aflibercept were linked to central nervous system vascular disorders (sROR, 5.57[95%CI, 4.95‐6.26] vs sROR, 2.23 [95%CI, 1.75‐2.85] vs sROR, 2.73[95%CI, 2.43–3.06]), ischemic heart disease (sROR, 3.31[95%CI, 2.65–4.13] vs sROR, 1.98 [95%CI, 1.24‐3.16] vs sROR, 3.00 [95%CI, 2.46‐3.65]), embolic and thrombotic (sROR, 3.36 [95%CI, 3.04‐3.72] vs sROR, 2.16 [95%CI, 1.70‐2.74] vs sROR, 5.25 [95%CI, 4.82‐5.72]). Both ranibizumab and bevacizumab produced hypertension (sROR, 1.73 [95%CI, 1.41‐2.12] vs sROR, 1.46 [95%CI, 1.03‐2.06]) and arrhythmias (sROR, 2.82 [95%CI, 1.99‐3.99] vs sROR, 2.13 [95%CI, 1.08‐4.22]) signals. The signals of heart failure were detected in ranibizumab (sROR, 5.64 [95%CI, 4.08‐7.79]) and aflibercept (sROR, 2.80 [95%CI, 2.03‐3.86]). Ranibizumab, bevacizumab, and aflibercept for ocular disease have different safety profiles in cardiovascular and cerebrovascular. The overall cardiovascular and cerebrovascular risk of the patient should be thoroughly assessed in order to select the safest drug for treatment. [ABSTRACT FROM AUTHOR]

This study examined the dissolution release performance of slow-release phosphate glass (SRPG), and the role this element plays in water and soil contaminated with heavy metals. It is known that the rate of dissolution ternary phosphate glass asXMgO–(50-X)Na2O–50P2O5(mol %) may be controlled by adjusting its content of MgO. The results showed that SRPG was uniformly dissolved in deionized water. Acidic or basic conditions induced the dissolution of SRPG; in contrast, lysate of SRPG in water decreased its rate of dissolution. Phosphate glass treatment of heavy metal lead (Pb)-contaminated soil effectively reduced the Pb content in H2O and MgCl2extracts by 81.6% and 75.7%, respectively. Comparative tests showed that leaf and root portion of Pb uptake in cabbage grown in soil treated with SRPG was reduced by 65.1% and 51.6% compared to untreated soil. Analysis of SRPG with Pb immobilization in water and soil environment by X-ray diffraction demonstrated that low-solubility phosphate (PbHPO4) and hydroxyphosphate [Pb5(PO4)3OH] complex was formed. Data indicate that SRPG may be effective in removal of Pb from contaminated soils and diminish risk of toxicity from ingestion of this heavy metal by consumers. [ABSTRACT FROM PUBLISHER]